Immatics Biotechnologies Gmbh

Universitãt Stuttgart

Meike Hutt

Felix Unverdorben

Claudia Wagner

Dominik Maurer

Sebastian Bunk

Martin Hofmann

Heiko Schuster

Leonie Alten

Roland Kontermann

Gabriele Pszolla

Frank Schwoebel

Oliver Seifert

Sara Yousef

Ugur Sahin

Klaus Pfizenmaier

Stefan Dubel

Martin Siegemund

Monilola Olayioye

Michael Hust

Stefan Dübel

Jonas Zantow

Maike Jaworski

Florian Schwoerer

Lisa Schmitt

The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Antigen binding proteins specifically binding MAGE-A

The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Engineered T cell receptors and immune therapy using the same

The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Antigen binding proteins specifically binding PRAME

The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament. The invention further provides a method of inhibiting tumor growth or treating cancer, comprising administering a therapeutically effective amount of the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical.

Antigen binding protein against HER3

The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (C1) of an Ig molecule and their use for therapy and prophylaxis.

Serum half-life extension using IgBD

The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector. Further, the present invention relates to said polypeptides, said nucleic acid or said vector for the use as a medicament or for the use in the diagnosis, prophylaxis or treatment of hyperproliferative disorders and inflammatory disorders.

Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof

Growing community of inventors

Stuttgart, Germany

Meike Hutt